Physician profile
Robert Kukla
NPI 1871570697
$2,305.19
in general payments reported to CMS, 2019-2025
33 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $206 · 2021: $65.86 · 2022: $220 · 2023: $580 · 2024: $635 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579 · Entertainment: $23.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.01 |
| Entertainment | $23.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $421.74 | 2021-2025 | Puraply, Apligraf |
| Smith+Nephew, INC. | $250.23 | 2019-2025 | Evos, Grafix Pl, Bone Anchors With Arthroscopic Delivery System |
| Musculoskeletal Transplant Foundation INC. | $182.56 | 2020-2023 | |
| Imbed Biosciences INC. | $163.46 | 2023 | |
| Next Science LLC | $124.32 | 2023-2024 | Blastx, Surgx, Xperience |
| Convatec INC. | $120.13 | 2020-2025 | |
| Fusion Orthopedics USA, LLC | $108.35 | 2025 | |
| Fusion Orthopedics, LLC. | $97.40 | 2019 | |
| Paratek Pharmaceuticals, INC. | $93.56 | 2024-2025 | Nuzyra |
| Abbvie INC. | $72.84 | 2025 | |
| Bioventus LLC | $71.87 | 2022-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Orpyx Medical Technologies US INC. | $69.86 | 2022 | |
| Amgen INC. | $60.51 | 2024 | Krystexxa |
| Boston Scientific Corporation | $56.93 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Kerecis Limited | $48.14 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $44.93 | 2024-2025 | Activ.A.C. |
| Melinta Therapeutics, LLC | $41.57 | 2019 | |
| Zimmer Biomet Holdings, INC. | $29.41 | 2019-2020 | |
| Tactile Systems Technology INC | $24.11 | 2023 | Flexitouch Plus, Entre Plus |
| Globus Medical, INC. | $21.35 | 2025 | Senza |
| Mimedx Group, INC. | $21.21 | 2024 | |
| Treace Medical Concepts, INC. | $20.37 | 2023 | |
| Nevro Corp. | $19.58 | 2024 | Senza |
| Abbott Laboratories | $16.92 | 2019 | |
| Inari Medical, INC. | $16.43 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pacira Pharmaceuticals Incorporated | $16.36 | 2021 | |
| Averitas Pharma INC. | $16.32 | 2024 | Qutenza |
| Medtronic, INC. | $15.03 | 2022 | |
| Kci USA, INC. | $14.92 | 2023 | Activ.A.C., Promogran Prisma, Snap |
| Forte Bio-Pharma LLC | $14.60 | 2019 | |
| Medela LLC | $13.71 | 2020 | |
| Zyla Life Sciences, INC. | $13.21 | 2019 | |
| Advanced Oxygen Therapy INC. | $3.26 | 2023 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.